Conclusion

Taken together, numerous findings in recent years have considerably boosted the understanding of the structure and function of the BBB in physiological and pathological conditions. Moreover, there is a growing body of evidence showing that the disruption of the BBB plays an essential role in the development of CNS disorders.

Here we demonstrated that cuprizone is specifically toxic for mature oligodendrocytes.

Second, the fumaric acid ester, DMF does not restore the loss of tight junction protein after an inflammatory insult. Moreover, MSC do not migrate into cuprizone- induced lesions in the brain and thus have no effects on the demyelination course of the disease. Finally, the perinatal inflammation induces a long-term effect of the BBB structure. Our data add up some findings to the complex puzzle of the modulatory effect of several substances on BBB structure.

106

107

References

Abbott NJ (2000) Inflammatory mediators and modulation of blood-brain barrier permeability. Cellular and molecular neurobiology 20:131-147.

Abbott NJ, Revest PA (1991) Control of brain endothelial permeability. Cerebrovascular and brain metabolism reviews 3:39-72.

Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nature reviews Neuroscience 7:41-53.

Abbott NJ, Dolman DE, Patabendige AK (2008) Assays to predict drug permeation across the blood-brain barrier, and distribution to brain. Current drug metabolism 9:901-910.

Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiology of disease 37:13-25.

Abbott NJ, Khan EU, Rollinson CM, Reichel A, Janigro D, Dombrowski SM, Dobbie MS, Begley DJ (2002) Drug resistance in epilepsy: the role of the blood-brain barrier. Novartis Foundation symposium 243:38-47; discussion 47-53, 180-185.

Afonso PV, Ozden S, Prevost MC, Schmitt C, Seilhean D, Weksler B, Couraud PO, Gessain A, Romero IA, Ceccaldi PE (2007) Human blood-brain barrier disruption by retroviral-infected lymphocytes: role of myosin light chain kinase in endothelial tight-junction disorganization. J Immunol 179:2576-2583.

Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, Johansson BR, Betsholtz C (2010) Pericytes regulate the blood-brain barrier. Nature 468:557-561.

Ascherio A, Munger KL (2010) Epstein-barr virus infection and multiple sclerosis: a review. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 5:271-277.

Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ, Hankinson SE, Hunter DJ (2001) Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA : the journal of the American Medical Association 286:3083-3088.

Audus KL, Borchardt RT (1986) Characteristics of the large neutral amino acid transport system of bovine brain microvessel endothelial cell monolayers. Journal of neurochemistry 47:484-488.

Banks WA (2005) Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Current pharmaceutical design 11:973-984.

Bar-Or A (2005) Immunology of multiple sclerosis. Neurologic clinics 23:149-175, vii.

Bar-Or A (2008) The immunology of multiple sclerosis. Seminars in neurology 28:29-45.

Begley DJ, Brightman MW (2003) Structural and functional aspects of the blood-brain barrier. Progress in drug research Fortschritte der Arzneimittelforschung Progres des recherches pharmaceutiques 61:39-78.

Belanger M, Asashima T, Ohtsuki S, Yamaguchi H, Ito S, Terasaki T (2007) Hyperammonemia induces transport of taurine and creatine and suppresses claudin-12 gene expression in brain capillary endothelial cells in vitro. Neurochemistry international 50:95-101.

Bernacki J, Dobrowolska A, Nierwinska K, Malecki A (2008) Physiology and pharmacological role of the blood-brain barrier. Pharmacological reports : PR 60:600-622.

108 Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J (1997) Myelin oligodendrocyte

glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med (Berl) 75:77-88.

Blakemore WF (2005) The case for a central nervous system (CNS) origin for the Schwann cells that remyelinate CNS axons following concurrent loss of oligodendrocytes and astrocytes. Neuropathology and applied neurobiology 31:1-10.

Blakemore WF, Franklin RJ (2008) Remyelination in experimental models of toxin-induced demyelination.

Current topics in microbiology and immunology 318:193-212.

Blasig IE, Mertsch K, Haseloff RF (2002) Nitronyl nitroxides, a novel group of protective agents against oxidative stress in endothelial cells forming the blood-brain barrier. Neuropharmacology 43:1006-1014.

Bowman PD, Ennis SR, Rarey KE, Betz AL, Goldstein GW (1983) Brain microvessel endothelial cells in tissue culture: a model for study of blood-brain barrier permeability. Annals of neurology 14:396-402.

Bradl M, Lassmann H (2009) Progressive multiple sclerosis. Seminars in immunopathology 31:455-465.

Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH (2009) Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet neurology 8:244-253.

Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P (2010) A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 74:1852-1859.

Cai Z, Pan ZL, Pang Y, Evans OB, Rhodes PG (2000) Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration. Pediatric research 47:64-72.

Calabrese V, Raffaele R, Cosentino E, Rizza V (1994) Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. International journal of clinical pharmacology research 14:119-123.

Cao X, Chen G, He L, Zhang W, Yu Y, Wang J (1997) Involvement of MHC class I molecule and ICAM-1 in the enhancement of adhesion and cytotoxic susceptibility to immune effector cells of tumor cells transfected with the interleukin (IL)-2, IL-4 or IL-6 gene. Journal of cancer research and clinical oncology 123:602-608.

Cecchelli R, Dehouck B, Descamps L, Fenart L, Buee-Scherrer VV, Duhem C, Lundquist S, Rentfel M, Torpier G, Dehouck MP (1999) In vitro model for evaluating drug transport across the blood-brain barrier.

Advanced drug delivery reviews 36:165-178.

Citi S, Cordenonsi M (1998) Tight junction proteins. Biochimica et biophysica acta 1448:1-11.

Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221-1231.

Correale J, Villa A (2007) The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting. Autoimmunity 40:148-160.

Crang AJ, Gilson JM, Li WW, Blakemore WF (2004) The remyelinating potential and in vitro differentiation of MOG-expressing oligodendrocyte precursors isolated from the adult rat CNS. The European journal of neuroscience 20:1445-1460.

Cucullo L, Hossain M, Rapp E, Manders T, Marchi N, Janigro D (2007) Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 48:505-516.

de Vries HE, Kuiper J, de Boer AG, Van Berkel TJ, Breimer DD (1997) The blood-brain barrier in neuroinflammatory diseases. Pharmacological reviews 49:143-155.

109 Dhuria SV, Hanson LR, Frey WH, 2nd (2010) Intranasal delivery to the central nervous system: mechanisms and

experimental considerations. Journal of pharmaceutical sciences 99:1654-1673.

Di F, Yan-Ting G, Hui L, Tao T, Zai-Hua X, Xue-Ying S, Hong-Li X, Yun-Jie W (2008) Role of aminoguanidine in brain protection in surgical brain injury in rat. Neuroscience letters 448:204-207.

Dinkova-Kostova AT, Holtzclaw WD, Kensler TW (2005) The role of Keap1 in cellular protective responses.

Chemical research in toxicology 18:1779-1791.

Dore-Duffy P (2008) Pericytes: pluripotent cells of the blood brain barrier. Current pharmaceutical design 14:1581-1593.

Duncan JR, Cock ML, Scheerlinck JP, Westcott KT, McLean C, Harding R, Rees SM (2002) White matter injury after repeated endotoxin exposure in the preterm ovine fetus. Pediatric research 52:941-949.

Dunn AJ, Wang J, Ando T (1999) Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Advances in experimental medicine and biology 461:117-127.

Dutta R, Trapp BD (2007) Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68:S22-31; discussion S43-54.

Dyment DA, Ebers GC, Sadovnick AD (2004) Genetics of multiple sclerosis. Lancet neurology 3:104-110.

Ehrlich P (1885) Das sauerstufbudurfnis des organismus, in Eine Farbenanalytische Studie.

Engelhardt B, Sorokin L (2009) The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Seminars in immunopathology 31:497-511.

Fazakerley JK, Walker R (2003) Virus demyelination. Journal of neurovirology 9:148-164.

Feldman GJ, Mullin JM, Ryan MP (2005) Occludin: structure, function and regulation. Advanced drug delivery reviews 57:883-917.

Fenstermacher J, Gross P, Sposito N, Acuff V, Pettersen S, Gruber K (1988) Structural and functional variations in capillary systems within the brain. Annals of the New York Academy of Sciences 529:21-30.

Ferretti G, Bacchetti T, Principi F, Di Ludovico F, Viti B, Angeleri VA, Danni M, Provinciali L (2005) Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 11:677-682.

Fiuza C, Suffredini AF (2001) Human models of innate immunity: local and systemic inflammatory responses.

Journal of endotoxin research 7:385-388.

Franke H, Galla HJ, Beuckmann CT (1999) An improved low-permeability in vitro-model of the blood-brain barrier: transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain research 818:65-71.

Franklin RJ, Kotter MR (2008) The biology of CNS remyelination: the key to therapeutic advances. Journal of neurology 255 Suppl 1:19-25.

Franklin RJ, Ffrench-Constant C (2008) Remyelination in the CNS: from biology to therapy. Nature reviews Neuroscience 9:839-855.

Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis--the plaque and its pathogenesis. The New England journal of medicine 354:942-955.

Furuse M (2006) [Molecular mechanism behind the barrier function of tight junctions]. Seikagaku The Journal of Japanese Biochemical Society 78:601-608.

110 Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S (1993) Occludin: a novel integral membrane

protein localizing at tight junctions. The Journal of cell biology 123:1777-1788.

Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiology of disease 37:48-57.

Gay FW, Drye TJ, Dick GW, Esiri MM (1997) The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain : a journal of neurology 120 ( Pt 8):1461-1483.

Gogel S, Gubernator M, Minger SL (2011) Progress and prospects: stem cells and neurological diseases. Gene therapy 18:1-6.

Gold R, Linker RA, Stangel M (2011) Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol 142:44-48.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

The New England journal of medicine 367:1098-1107.

Gold SM, Sasidhar MV, Morales LB, Du S, Sicotte NL, Tiwari-Woodruff SK, Voskuhl RR (2009) Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Laboratory investigation; a journal of technical methods and pathology 89:1076-1083.

Goldstein GW, Betz AL (1983) Recent advances in understanding brain capillary function. Annals of neurology 14:389-395.

Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE (2003) Tight junction proteins. Progress in biophysics and molecular biology 81:1-44.

Gordon D, Pavlovska G, Uney JB, Wraith DC, Scolding NJ (2010) Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis. Journal of neuropathology and experimental neurology 69:1087-1095.

Gourraud PA, Harbo HF, Hauser SL, Baranzini SE (2012) The genetics of multiple sclerosis: an up-to-date review. Immunological reviews 248:87-103.

Greco A, Minghetti L, Sette G, Fieschi C, Levi G (1999) Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 53:1876-1879.

Gudi V, Moharregh-Khiabani D, Skripuletz T, Koutsoudaki PN, Kotsiari A, Skuljec J, Trebst C, Stangel M (2009) Regional differences between grey and white matter in cuprizone induced demyelination. Brain research 1283:127-138.

Gutmann H, Torok M, Fricker G, Huwyler J, Beglinger C, Drewe J (1999) Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro. Drug metabolism and disposition:

the biological fate of chemicals 27:937-941.

Gutmann H, Bruggisser R, Schaffner W, Bogman K, Botomino A, Drewe J (2002) Transport of amentoflavone across the blood-brain barrier in vitro. Planta medica 68:804-807.

Hafler DA (2004) Multiple sclerosis. The Journal of clinical investigation 113:788-794.

Hartz AM, Bauer B, Fricker G, Miller DS (2006) Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Molecular pharmacology 69:462-470.

Hawkes CH (2007) Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult Scler 13:610-615.

111 Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacological

reviews 57:173-185.

Heiskala M, Peterson PA, Yang Y (2001) The roles of claudin superfamily proteins in paracellular transport.

Traffic 2:93-98.

Hickey MJ (2001a) Role of inducible nitric oxide synthase in the regulation of leucocyte recruitment. Clin Sci (Lond) 100:1-12.

Hickey WF (2001b) Basic principles of immunological surveillance of the normal central nervous system. Glia 36:118-124.

Hudson LD, Puckett C, Berndt J, Chan J, Gencic S (1989) Mutation of the proteolipid protein gene PLP in a human X chromosome-linked myelin disorder. Proceedings of the National Academy of Sciences of the United States of America 86:8128-8131.

Joo F, Karnushina I (1973) A procedure for the isolation of capillaries from rat brain. Cytobios 8:41-48.

Kacem K, Lacombe P, Seylaz J, Bonvento G (1998) Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: a confocal microscopy study. Glia 23:1-10.

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372:1463-1472.

Karg E, Klivenyi P, Nemeth I, Bencsik K, Pinter S, Vecsei L (1999) Nonenzymatic antioxidants of blood in multiple sclerosis. Journal of neurology 246:533-539.

Karussis D, Kassis I (2008) The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience. Clinical neurology and neurosurgery 110:889-896.

Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Archives of neurology 67:1187-1194.

Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annual review of pharmacology and toxicology 47:89-116.

Kniesel U, Wolburg H (2000) Tight junctions of the blood-brain barrier. Cellular and molecular neurobiology 20:57-76.

Koch-Henriksen N, Sorensen PS (2010) The changing demographic pattern of multiple sclerosis epidemiology.

Lancet neurology 9:520-532.

Koch M, Ramsaransing GS, Arutjunyan AV, Stepanov M, Teelken A, Heersema DJ, De Keyser J (2006) Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. Journal of neurology 253:483-487.

Koutsoudaki PN, Skripuletz T, Gudi V, Moharregh-Khiabani D, Hildebrandt H, Trebst C, Stangel M (2009) Demyelination of the hippocampus is prominent in the cuprizone model. Neuroscience letters 451:83-88.

Krishnamoorthy G, Wekerle H (2009) EAE: an immunologist's magic eye. European journal of immunology 39:2031-2035.

Krizanac-Bengez L, Kapural M, Parkinson F, Cucullo L, Hossain M, Mayberg MR, Janigro D (2003) Effects of transient loss of shear stress on blood-brain barrier endothelium: role of nitric oxide and IL-6. Brain research 977:239-246.

112 Kurzepa J, Bartosik-Psujek H, Suchozebrska-Jesionek D, Rejdak K, Stryjecka-Zimmer M, Stelmasiak Z (2005) Role of matrix metalloproteinases in the pathogenesis of multiple sclerosis. Neurologia i neurochirurgia polska 39:63-67.

Lassmann H (2008) Mechanisms of inflammation induced tissue injury in multiple sclerosis. Journal of the neurological sciences 274:45-47.

Lassmann H, Schwerer B, Kitz K, Egghart M, Bernheimer H (1983) Pathogenetic aspects of demyelinating lesions in chronic relapsing experimental allergic encephalomyelitis: possible interaction of cellular and humoral immune mechanisms. Progress in brain research 59:305-315.

Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ, Johnson JA (2005) Nrf2, a multi-organ protector? FASEB journal : official publication of the Federation of American Societies for Experimental Biology 19:1061-1066.

Lewandowsky M (1900) Zur lehre von der cerebrospinalflussigkeit. Z Klin Med 40:480–494.

Li SF, Lu XF, Sun MH (2002) Biological characteristics of mesenchymal stem cells in vitro derived from bone marrow of banna minipig inbred line. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery 16:354-358.

Lindberg RL, De Groot CJ, Montagne L, Freitag P, van der Valk P, Kappos L, Leppert D (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain : a journal of neurology 124:1743-1753.

Lindner M, Fokuhl J, Linsmeier F, Trebst C, Stangel M (2009) Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neuroscience letters 453:120-125.

Linington C, Lassmann H (1987) Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). Journal of neuroimmunology 17:61-69.

Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. The American journal of pathology 130:443-454.

Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Bruck W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain : a journal of neurology 134:678-692.

Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907-911.

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (1999) A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain : a journal of neurology 122 ( Pt 12):2279-2295.

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of neurology 47:707-717.

Lukashev D, Sitkovsky M (2008) Preferential expression of the novel alternative isoform I.3 of hypoxia-inducible factor 1alpha in activated human T lymphocytes. Human immunology 69:421-425.

Maghzi AH, Ghazavi H, Ahsan M, Etemadifar M, Mousavi S, Khorvash F, Minagar A (2010) Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study. Mult Scler 16:359-361.

113 Male D, Pryce G, Linke A, Rahman J (1992) Lymphocyte migration into the CNS modelled in vitro. Journal of

neuroimmunology 40:167-171.

Marroni M, Kight KM, Hossain M, Cucullo L, Desai SY, Janigro D (2003) Dynamic in vitro model of the blood-brain barrier. Gene profiling using cDNA microarray analysis. Methods in molecular medicine 89:419-434.

Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D, Dejana E (1998) Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. The Journal of cell biology 142:117-127.

Mason JL, Ye P, Suzuki K, D'Ercole AJ, Matsushima GK (2000) Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. The Journal of neuroscience : the official journal of the Society for Neuroscience 20:5703-5708.

Mason JL, Toews A, Hostettler JD, Morell P, Suzuki K, Goldman JE, Matsushima GK (2004) Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions. The American journal of pathology 164:1673-1682.

Massacesi L, Abbamondi AL, Raimondi L, Giorgi C, Amaducci L (1988) Lysosomal enzymes in experimental allergic encephalomyelitis: time course and evidence of the source. Neurochemical research 13:165-169.

Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107-116.

Matter K, Balda MS (2003) Holey barrier: claudins and the regulation of brain endothelial permeability. The Journal of cell biology 161:459-460.

Megard I, Garrigues A, Orlowski S, Jorajuria S, Clayette P, Ezan E, Mabondzo A (2002) A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. Brain research 927:153-167.

Mezey E, Chandross KJ (2000) Bone marrow: a possible alternative source of cells in the adult nervous system.

European journal of pharmacology 405:297-302.

Mi H, Haeberle H, Barres BA (2001) Induction of astrocyte differentiation by endothelial cells. The Journal of neuroscience : the official journal of the Society for Neuroscience 21:1538-1547.

Miller DH, Leary SM (2007) Primary-progressive multiple sclerosis. Lancet neurology 6:903-912.

Minagar A, Jy W, Jimenez JJ, Alexander JS (2006) Multiple sclerosis as a vascular disease. Neurological research 28:230-235.

Minagar A, Ostanin D, Long AC, Jennings M, Kelley RE, Sasaki M, Alexander JS (2003) Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells.

Mult Scler 9:235-238.

MohanKumar SM, MohanKumar PS, Quadri SK (1999) Lipopolysaccharide-induced changes in monoamines in specific areas of the brain: blockade by interleukin-1 receptor antagonist. Brain research 824:232-237.

Morell P, Barrett CV, Mason JL, Toews AD, Hostettler JD, Knapp GW, Matsushima GK (1998) Gene expression in brain during cuprizone-induced demyelination and remyelination. Molecular and cellular neurosciences 12:220-227.

Motohashi H, Yamamoto M (2004) Nrf2-Keap1 defines a physiologically important stress response mechanism.

Trends in molecular medicine 10:549-557.

114 Mrowietz U, Asadullah K (2005) Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends in

molecular medicine 11:43-48.

Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, Ascherio A (2004) Vitamin D intake and incidence of multiple sclerosis. Neurology 62:60-65.

Nadal A, Fuentes E, Pastor J, McNaughton PA (1995) Plasma albumin is a potent trigger of calcium signals and DNA synthesis in astrocytes. Proceedings of the National Academy of Sciences of the United States of America 92:1426-1430.

Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. The Journal of cell biology 161:653-660.

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. The New England journal of medicine 343:938-952.

Nusrat A, Brown GT, Tom J, Drake A, Bui TT, Quan C, Mrsny RJ (2005) Multiple protein interactions involving proposed extracellular loop domains of the tight junction protein occludin. Molecular biology of the cell 16:1725-1734.

Ohtsuki S, Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development.

Ohtsuki S, Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development.

Im Dokument Modulation of the blood-brain barrier (Seite 117-135)